fluticasone furoate/umeclidinium/vilanterol vs Olodaterol/tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02164513 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).
Next expected readout: September 2027 · NCT07192016 (registry estimate)
Reported efficacy
Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)
Result source: NCT02164513
Olodaterol/tiotropium bromide
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/umeclidinium/vilanterol | Olodaterol/tiotropium bromide |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.9 vs 1.1vs FF/VINCT021645132 other results
| —Not reported |
| Trough FEV1, change | 0.1 vs -0.0vs BUD/FORNCT0234516114 other results
| —Not reported |
| SGRQ total, change | -6.6 vs -4.3vs BUD/FORNCT023451613 other results
| —Not reported |
| TDI focal score | 2.3 vs 1.7vs BUD/FORNCT023451611 other result
| —Not reported |
Moderate or severe exacerbations, annualised rate
- fluticasone furoate/umeclidinium/vilanterol
- 0.9 vs 1.1vs FF/VINCT02164513
2 other results
- 0.2 vs 0.3 NCT02345161
- 0.2 vs 0.4 NCT02345161
- Olodaterol/tiotropium bromide
- —Not reported
Trough FEV1, change
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs -0.0vs BUD/FORNCT02345161
14 other results
- 0.1 vs -0.1 NCT02345161
- 0.1 vs 0.1 NCT02729051
- 0.1 vs -0.0 NCT02164513
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs -0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.0 vs -0.0 NCT03478696
- 0.0 vs 0.0 NCT03478683
- Olodaterol/tiotropium bromide
- —Not reported
SGRQ total, change
- fluticasone furoate/umeclidinium/vilanterol
- -6.6 vs -4.3vs BUD/FORNCT02345161
3 other results
- -4.6 vs -1.9 NCT02345161
- -5.5 vs -3.7 NCT02164513
- -5.8 vs -4.9 NCT02729051
- Olodaterol/tiotropium bromide
- —Not reported
TDI focal score
- fluticasone furoate/umeclidinium/vilanterol
- 2.3 vs 1.7vs BUD/FORNCT02345161
1 other result
- 1.7 vs 1.4 NCT02345161
- Olodaterol/tiotropium bromide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Olodaterol/tiotropium bromide: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · Olodaterol/tiotropium bromide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol |
|---|---|
| Dropout rate | 10.5%FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 4.9%100/62.5/25 µg NCT02345161 · Phase 3 6.1% NCT04923347 · Phase 4 · registry result, not featured evidence 9.5% NCT05535972 · Phase 4 · registry result, not featured evidence 3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 4.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.6%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 3.6%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.9%FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 1.8%100/62.5/25 µg NCT02345161 · Phase 3 — NCT04923347 · Phase 4 · registry result, not featured evidence 1.3% NCT05535972 · Phase 4 · registry result, not featured evidence 0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 1.5%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 0.3%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 1.4%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Serious AEs | —FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results21.6%100/62.5/25 NCT02164513 · Phase 3 6.7%100/62.5/25 µg NCT02345161 · Phase 3 0.4% NCT04923347 · Phase 4 · registry result, not featured evidence 4.1% NCT05535972 · Phase 4 · registry result, not featured evidence 7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 3.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.4%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 8%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 100/62.5/25a viral upper respiratory tract infection 12.5% upper respiratory tract infection 7.2% headache 5.6% NCT02164513 · Phase 3 show 8 more resultsdysphonia 0.4% abdominal discomfort 0.2% abdominal pain upper 0.2% NCT05535972 · Phase 4 · registry result, not featured evidence 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI dyspnoea 2.1% NCT03467425 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 4.5% nasopharyngitis 4% NCT03474081 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 3.6% nasopharyngitis 1.9% NCT03478696 · Phase 4 · registry result, not featured evidence 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 2 more results
show 14 more results
show 3 more results
show 1 more result
show 1 more result
show 17 more results
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Olodaterol/tiotropium bromide's landscape